causal
Anchor-investor funding enabled Argenx's late-stage trials
A US-based long-term investor, OrbiMed, joined early, providing capital and aligning the company toward a long-term platform strategy rather than a one-asset sale, which changed the company's strategy and independence.
causalpending
Speaker
JuliaEvidence Quote
“they don't need to be one asset company, but actually, they are platform-based”
Created: 11/17/2026, 3:39:21 AM
Your notes
Loading notes...